DESTINY-Breast03 — Trastuzumab Deruxtecan vs Trastuzumab Emtansine in HER2-Positive Metastatic Breast Cancer

Phase 3 · 2022 · Breast Cancer

Design

Randomized 1:1 to trastuzumab deruxtecan vs trastuzumab emtansine (T-DM1) in previously treated HER2-positive disease.

Population

HER2-positive metastatic breast cancer previously treated with trastuzumab and a taxane.

Primary Endpoint

progression-free survival (PFS)

Key Result

Median PFS 28.8 vs 6.8 mo (HR 0.33); 12-mo OS 94.1% vs 85.9%; ORR 79% vs 35%.

Guideline Impact

NCCN preferred category 1 second-line HER2-positive MBC